Dataset Information

Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.

ABSTRACT: Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, potent BCL-XL antagonists containing an undesirable hydrazone functionality, in silico design and X-ray crystallography were utilized to develop alternative scaffolds that retained the selectivity and potency of the starting compounds.

SUBMITTER: Koehler MF

PROVIDER: S-EPMC4060937 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.

Koehler Michael F T MF Bergeron Philippe P Choo Edna F EF Lau Kevin K Ndubaku Chudi C Dudley Danette D Gibbons Paul P Sleebs Brad E BE Rye Carl S CS Nikolakopoulos George G Bui Chinh C Kulasegaram Sanji S Kersten Wilhelmus J A WJ Smith Brian J BJ Czabotar Peter E PE Colman Peter M PM Huang David C S DC Baell Jonathan B JB Watson Keith G KG Hasvold Lisa L Tao Zhi-Fu ZF Wang Le L Souers Andrew J AJ Elmore Steven W SW Flygare John A JA Fairbrother Wayne J WJ Lessene Guillaume G

ACS medicinal chemistry letters 20140321 6

Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, potent BCL-XL antagonists containing an undesirable hydrazone functionality, in silico design and X-ray crystallography were utilized to develop alternative scaffolds that retained the selectivity and potency of the starting compounds. ...[more]

PMID: 24944740

Similar Datasets

Project description:Development of resistance to chemo- and radiotherapy in patients suffering from advanced cervical cancer narrows the therapeutic window for conventional therapies. Previously we reported that a combination of the selective BCL-2 family inhibitors ABT-263 and A-1210477 decreased cell proliferation in C33A, SiHa and CaSki human cervical cancer cell lines. As ABT-263 binds to both BCL-2 and BCL-XL with high affinity, it was unclear whether the synergism of the drug combination was driven either by singly inhibiting BCL-2 or BCL-XL, or inhibition of both. In this present study, we used the BCL-2 selective inhibitor ABT-199 and the BCL-XL selective inhibitor A1331852 to resolve the individual antitumor activities of ABT-263 into BCL-2 and BCL-XL dependent mechanisms. A-1210477 was substituted for the orally bioavailable S63845. Four cervical cancer cell lines were treated with the selective BCL-2 family inhibitors ABT-199, A1331852 and S63845 alone and in combination using 2-dimensional (2D) and 3-dimensional (3D) cell culture models. The SiHa, C33A and CaSki cell lines were resistant to single agent treatment of all three drugs, suggesting that none of the BCL-2 family of proteins mediate survival of the cells in isolation. HeLa cells were resistant to single agent treatment of ABT-199 and A1331852 but were sensitive to S63845 indicating that they depend on MCL-1 for survival. Co-inhibition of BCL-2 and MCL-1 with ABT-199 and S63845, inhibited cell proliferation of all cancer cell lines, except SiHa. However, the effect of the combination was not as pronounced as combination of A1331852 and S63845. Co-inhibition of BCL-XL and MCL-1 with A1331852 and S63845 significantly inhibited cell proliferation of all four cell lines. Similar data were obtained with 3-dimensional spheroid cell culture models generated from two cervical cancer cell lines in vitro. Treatment with a combination of A1331852 and S63845 resulted in inhibition of growth and invasion of the 3D spheroids. Collectively, our data demonstrate that the combination of MCL-1-selective inhibitors with either selective inhibitors of either BCL-XL or BCL-2 may be potentially useful as treatment strategies for the management of cervical cancer.

Dataset Information

Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.

Publications

Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets